Tirzepatide for PCOS and insulin resistance: what TikTok gets right and wrong

What's this video probably claiming?

Based on the hashtag combination of #glp1, #insulinresistance, #pcos, #tirzepatide, and #zepbound, this creator is almost certainly sharing a personal journey using tirzepatide (Zepbound) for PCOS-related insulin resistance, and framing it as a solution for the condition. The #compoundtirzepatide tag is a red flag worth noting. The creator is likely claiming that tirzepatide addresses the root hormonal dysfunction in PCOS, possibly that it regulates cycles, reduces androgen symptoms like acne or hair loss, and improves fertility outcomes. This type of content is everywhere right now, and it blurs the line between someone sharing a real experience and someone making implicit medical claims that could influence 122,000+ viewers into seeking compounded tirzepatide without proper evaluation.

What does the science actually show?

The honest answer is: tirzepatide shows real promise for PCOS, but the evidence base is thin and the mechanism story is more complicated than TikTok makes it sound. PCOS is driven by hyperandrogenism, ovulatory dysfunction, and frequently insulin resistance, and dual GIP/GLP-1 receptor agonists like tirzepatide do target that insulin resistance pathway. A 2023 study by Fruzzetti et al. in Frontiers in Endocrinology showed GLP-1 receptor agonists improved menstrual regularity and androgen levels in women with PCOS and obesity, though most data is from liraglutide and semaglutide, not tirzepatide specifically. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide producing up to 22.5% body weight reduction at 15mg over 72 weeks, and weight loss alone independently improves PCOS symptoms. But weight loss is not the same as treating PCOS as a disease, and tirzepatide is not FDA-approved for PCOS.

Where does the social media noise diverge from clinical reality?

The gap between what's being claimed on TikTok and what clinicians actually know is significant. First, most PCOS-GLP-1 research uses semaglutide or liraglutide. Extrapolating those results to tirzepatide is plausible but not validated in large PCOS-specific trials as of early 2025. Second, the #compoundtirzepatide hashtag implies the creator may be using or advocating for compounded versions of the drug. Compounded tirzepatide is not the same as FDA-approved Zepbound, full stop. The FDA has raised concerns about compounded GLP-1 products, and there is no clinical data on their purity, potency, or safety profile. Third, personal anecdotes about cycle regulation or fertility improvements, while meaningful to individuals, are not evidence of efficacy. PCOS symptom variability is high, and post hoc attribution of improvement to a single drug without controlled conditions is unreliable data.

What should you actually know?

If you have PCOS and insulin resistance and you're curious about tirzepatide, that is a reasonable conversation to have with an endocrinologist or a reproductive medicine specialist. The drug does address insulin resistance through a mechanism that is genuinely relevant to PCOS pathophysiology. A 2024 analysis by Mounjaro's manufacturer (Eli Lilly) and independent researchers suggested tirzepatide outperforms semaglutide on insulin sensitivity markers, which could theoretically translate to better PCOS outcomes, but that study was not PCOS-specific. What you should not do is source compounded tirzepatide based on a TikTok video, assume the drug will restore fertility or fix androgen-driven symptoms on a predictable timeline, or equate your neighbor's or a creator's experience with a clinical outcome that applies to you. PCOS is heterogeneous. What works for someone without insulin resistance, or with a different hormonal profile, may not apply to your case.